Journal
IMMUNOTHERAPY
Volume 12, Issue 15, Pages 1121-1126Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2020-0136
Keywords
COVID-19; cytokine-release syndrome; GM-CSF; IL-6; inflammatory markers; lenzilumab; monoclonal antibody; pneumonia; severe acute respiratory distress syndrome; tocilizumab
Categories
Ask authors/readers for more resources
Background: Coronavirus disease 2019 (COVID-19) is a novel disease associated with a cytokine-mediated, severe, acute respiratory syndrome. Tocilizumab and lenzilumab are recombinant monoclonal antibodies against IL-6 and granulocyte macrophage colony-stimulating factor, respectively, and have been proposed as a potential treatment for acute, hypoxic respiratory failure associated with COVID-19. Results & methodology: We present the case of a 68-year-old man with COVID-19 who was initially treated with hydroxychloroquine and lenzilumab, but continued to develop hypoxemia, requiring an increase in respiratory support with an associated rise in serum inflammatory markers. He was subsequently treated with tocilizumab with marked clinical improvement and a decrease in acute phase reactants within 48 h. Discussion & conclusion: This case demonstrates the effective use of tocilizumab in the treatment of COVID-19 and suggests the superiority of tocilizumab over lenzilumab in the management of this cytokine-mediated syndrome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available